Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy

Genes and Cancer

Volumn 7, Issue 3-4, 2016, Pages 86-97

  Vinall, Ruth L ^a,c   Tepper, Clifford G ^a   Ripoll, Alexandra A Z ^a   Gandour Edwards, Regina F ^a   Durbin Johnson, Blythe P ^a   Yap, Stanley A ^a   Ghosh, Paramita M ^a,b   Devere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

Author keywords

Chemoresistance; Let 7c; MiRNA; Muscle invasive bladder cancer; Neoadjuvant chemotherapy

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; GEMCITABINE; MICRORNA; PACLITAXEL;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DNA EXTRACTION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; LET 7C GENE; LYMPH VESSEL METASTASIS; MALE; MICROARRAY ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; PRINCIPAL COMPONENT ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85014647812     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.18632/genesandcancer.103     Document Type: Article

References (39)

1. Rene NJ, Cury FB, Souhami L. Conservative treatment of invasive bladder cancer. Current oncology. 2009;16:36-47. PubMed PMID: 19672423; PubMed Central PMCID: PMC2722049.
2. Turkolmez K, Tokgoz H, Resorlu B, Kose K, Beduk Y. Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. Urology. 2007;70:477-81. doi: 10.1016/j. urology.2007.05.008. PubMed PMID: 17905100.
3. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, et al. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European urology. 2015. doi: 10.1016/j.eururo.2015.01.032. PubMed PMID: 25709027.
4. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-66. doi: 10.1056/NEJMoa022148. PubMed PMID: 12944571.
5. Grossman HB; Cordon-Cardon S CR, Waldman FM, Tangen C, and Crawford ED. SWOG 9458: Evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 9710. International Journal of Cancer. 2002;Supplement 13:114.
6. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep. 2006;16:807-10. Epub 2006/09/14. PubMed PMID: 16969498.
7. Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Hall RR, et al. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res. 1999;5:3500-7. Epub 1999/12/10. PubMed PMID: 10589764.
8. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384-90. Epub 1995/06/01. PubMed PMID: 7751883.
9. Williams SG, Gandour-Edwards R, Deitch AD, Toscano S, Fan JJ, Sternberg CN, et al. Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. Eur Urol. 2001;39:430-7. Epub 2001/04/18. doi: eur39430 [pii]. PubMed PMID: 11306882.
10. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015;68:959-67. doi: 10.1016/j.eururo.2015.07.009. PubMed PMID: 26238431.
11. Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future oncology. 2014;10:1027-48. doi: 10.2217/fon.13.259. PubMed PMID: 24941988.
12. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA. microRNAs in cancer: from bench to bedside. Adv Cancer Res. 108:113-57. Epub 2010/11/03. doi: B978-0-12-380888-2.00004-2 [pii] 10.1016/B978-0-12-380888-2.00004-2. PubMed PMID: 21034967.
13. Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 2009. Epub 2009/09/23. doi: S0006-291X(09)01863-4 [pii] 10.1016/j.bbrc.2009.09.061. PubMed PMID: 19769940.
14. Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wyrich R, Thykjaer T, et al. Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn. 2007;9:452-8. Epub 2007/08/11. doi: jmoldx.2007.060175 [pii] 10.2353/jmoldx.2007.060175. PubMed PMID: 17690207; PubMed Central PMCID: PMC1975097.
15. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 9:306. Epub 2010/11/30. doi: 1476-4598-9-306 [pii] 10.1186/1476-4598-9-306. PubMed PMID: 21110877; PubMed Central PMCID: PMC3002336.
16. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126-36. Epub 2010/10/14. doi: 1535-7163.MCT-10-0397 [pii] 10.1158/1535-7163.MCT-10-0397. PubMed PMID: 20940321.
17. Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, et al. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 25:1721-9. Epub 2011/04/07. doi: 10.3892/or.2011.1245. PubMed PMID: 21468550.
18. Kozinn SI, Harty NJ, Delong JM, Deliyiannis C, Logvinenko T, Summerhayes IC, et al. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines. Genes Cancer. 4:61-9. Epub 2013/08/16. doi: 10.1177/1947601913484495 10.1177_1947601913484495 [pii]. PubMed PMID: 23946872; PubMed Central PMCID: PMC3743151.
19. Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173:1518-25. Epub 2005/04/12. doi: S0022-5347(05)60608-8 [pii] 10.1097/01. ju.0000154696.48217.75. PubMed PMID: 15821471.
20. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178:451-4. Epub 2007/06/15. doi: S0022-5347(07)00749-5 [pii] 10.1016/j. juro.2007.03.101. PubMed PMID: 17561135.
21. Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 81C:75-93. Epub 2014/09/16. doi: S0169-409X(14)00199-9 [pii] 10.1016/j.addr.2014.09.001. PubMed PMID: 25220354.
22. Jeffrey SS. Cancer biomarker profiling with microRNAs. Nat Biotechnol. 2008;26(4):400-1. Epub 2008/04/09. doi: nbt0408-400 [pii] 10.1038/nbt0408-400. PubMed PMID: 18392022.
23. Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 18:5144-53. Epub 2012/08/01. doi: 1078-0432.CCR-12-0701 [pii] 10.1158/1078-0432.CCR-12-0701. PubMed PMID: 22847808.
24. Li Y, VandenBoom TG, 2nd, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-12. Epub 2009/08/06. doi: 0008-5472.CAN-09-1298 [pii] 10.1158/0008-5472.CAN-09-1298. PubMed PMID: 19654291; PubMed Central PMCID: PMC2727571.
25. Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, et al. Let-7c Governs the Acquisition of Chemo-or Radioresistance and Epithelial-to-Mesenchymal Transition Phenotypes in Docetaxel-Resistant Lung Adenocarcinoma. Mol Cancer Res. 11:699-713. Epub 2013/04/09. doi: 1541-7786.MCR-13-0019-T [pii] 10.1158/1541-7786.MCR-13-0019-T. PubMed PMID: 23562878.
26. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 52:698-704. Epub 2010/03/30. doi: S0168-8278(10)00082-6 [pii] 10.1016/j.jhep.2009.12.024. PubMed PMID: 20347499.
27. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635-47. Epub 2005/03/16. doi: S0092-8674(05)00088-7 [pii] 10.1016/j.cell.2005.01.014. PubMed PMID: 15766527.
28. Gomez CR, Kosari F, Munz JM, Schreiber CA, Knutson GJ, Ida CM, et al. Prognostic value of discs large homolog 7 transcript levels in prostate cancer. PLoS One. 8:e82833. Epub 2013/12/19. doi: 10.1371/journal.pone.0082833 PONE-D-13-20821 [pii]. PubMed PMID: 24349376; PubMed Central PMCID: PMC3857287.
29. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315:1576-9. Epub 2007/02/27. doi: 1137999 [pii] 10.1126/science.1137999. PubMed PMID: 17322030; PubMed Central PMCID: PMC2556962.
30. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 28:401-8. Epub 2010/07/09. doi: S1078-1439(09)00146-X [pii] 10.1016/j.urolonc.2009.04.019. PubMed PMID: 20610278.
31. Canturk KM, Ozdemir M, Can C, Oner S, Emre R, Aslan H, et al. Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools. Mol Biol Rep. 2014;41:8127-35. doi: 10.1007/s11033-014-3713-5. PubMed PMID: 25189652.
32. Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One. 2014;9:e84311. doi: 10.1371/journal.pone.0084311. PubMed PMID: 24520312; PubMed Central PMCID: PMCPMC3919700.
33. Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao YC, et al. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival. Tumour Biol. 2015;36:8159-66. doi: 10.1007/s13277-015-3559-z. PubMed PMID: 25990459.
34. Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, et al. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 2015;34:53. doi: 10.1186/s13046-015-0167-0. PubMed PMID: 25991007; PubMed Central PMCID: PMCPMC4508815.
35. Shalgi R, Lieber D, Oren M, Pilpel Y. Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol. 2007;3:e131. Epub 2007/07/17. doi: 06-PLCB-RA-0543 [pii] 10.1371/journal.pcbi.0030131. PubMed PMID: 17630826; PubMed Central PMCID: PMC1914371.
36. Wang J, Lu M, Qiu C, Cui Q. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res. 38:D119-22. Epub 2009/09/30. doi: gkp803 [pii] 10.1093/nar/gkp803. PubMed PMID: 19786497; PubMed Central PMCID: PMC2808874.
37. Ziebold U, Lee EY, Bronson RT, Lees JA. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol. 2003;23:6542-52. Epub 2003/08/29. PubMed PMID: 12944480; PubMed Central PMCID: PMC193688.
38. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol. 2001;19:342-7. Epub 2001/04/03. doi: 10.1038/86730 86730 [pii]. PubMed PMID: 11283592.
39. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA. 2007;13:151-9. Epub 2006/11/16. doi: rna.234507 [pii] 10.1261/rna.234507. PubMed PMID: 17105992; PubMed Central PMCID: PMC1705746.